Enhanced Prostacyclin Antagonists for Ocular Surface Nociception Treatment

This inventive concept introduces novel formulations and administration methods for prostacyclin antagonists, enhancing the treatment of ocular surface nociception by minimizing adverse events, improving efficacy, and increasing patient comfort.

The original patent disclosed the use of prostacyclin antagonists for treating ocular pain, but had limitations in terms of formulation, administration, and potential side effects. This new inventive concept addresses these limitations by providing controlled release profiles, mucoadhesive polymers, combination therapies, and pulsatile administration methods.

The new claims introduce four distinct improvements to the original patent. Firstly, a controlled release profile is achieved through formulation, reducing peak plasma concentrations and minimizing the risk of adverse events. Secondly, a mucoadhesive polymer is incorporated into the topical ophthalmic formulation, enhancing the retention time of the formulation on the ocular surface and increasing treatment efficacy. Thirdly, a combination therapy with a lubricating agent is proposed, reducing friction on the ocular surface and enhancing patient comfort. Lastly, a pulsatile administration method is introduced, mimicking the natural pulsatile release of prostacyclin and reducing the risk of adverse events. These improvements collectively enhance the safety, efficacy, and comfort of ocular surface nociception treatment.

The new claims introduce novel and non-obvious improvements to the original patent, including controlled release profiles, mucoadhesive polymers, combination therapies, and pulsatile administration methods. These improvements are not suggested or implied in the original patent and provide a significant advancement in the field of ocular surface nociception treatment.

Alternative embodiments of this inventive concept could include different formulations, such as nanoparticles or liposomes, to further enhance the efficacy and safety of the treatment. Additionally, other combination therapies or administration methods could be explored to expand the scope of the inventive concept.

This inventive concept has significant commercial potential in the ophthalmic industry, particularly in the treatment of dry eye disease and other ocular surface disorders. The improved safety, efficacy, and comfort of the treatment could lead to increased adoption and market share.